Senores Pharmaceuticals Limited has informed the Exchange regarding completion of USFDA Inspection at Havix Group Inc. D/B/A Aavis Pharmaceuticals, Material Subsidiary of the Company.
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.7 pts more than Nifty Microcap 250 and 9.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Senores Pharmaceuticals' US-based material subsidiary, Havix Group Inc. (D/B/A Aavis Pharmaceuticals), underwent a USFDA inspection at its manufacturing facility in Hoschton, Georgia, from July 21 to July 25, 2025. The inspection concluded with 3 Form 483 observations, which the company describes as procedural and minor in nature. The subsidiary plans to submit its response to these observations within 15 days. No warning letter or import alert has been mentioned.
This is a routine regulatory disclosure with a relatively positive outcome — the inspection closed without escalation, and only minor procedural observations were noted. Short-term stock impact is likely limited, though investors should watch for the subsidiary's response and any follow-up action from the USFDA.